CLINICAL USES OF SCTZ–A PRELIMINARY REPORT
Abstract
Owing to the small number of cases treated so far, no firm conclusions can be drawn. The drug when administered intravenously produces sleep very rapidly which lasts for a few minutes only, thus necessitating frequent injections or recourse to an intravenous drip. The quantity required at one time varies from 100 to 160 c. c. In uncooperative cases when it is difficult to administer the drug, it can be injected after giving an ECT. Phlebitis appears to be a common complication and was met with in 5 cases. Further controlled trials are indicated.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
